Sol-Gel Technologies Ltd.
For the period ended Sep 17, 2026. Filed Sep 17, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Sep 17, 2026 · Filed Sep 17, 2026
Use the contents to explore the available documents and sections.
Contents
Explanatory Note
On September 17, 2026, Sol-Gel Technologies Ltd. (the “Company”) issued a press release announcing last patient last visit in pivotal Phase 3 clinical trial of SGT-610 in Gorlin Syndrome.
Attached hereto is the following exhibit:
Exhibit 99.1 Press release dated September 17, 2026
Exhibit 99.1 (other than the fourth paragraph thereof) is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (Registration Nos. 333-223915, 333-270477 and 333-286820) and its Registration Statements on Form F-3 (Registrations No. 333-286822 and 333-270478).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.